Loading…
PLX
Protalix BioTherapeutics, Inc.
NYSE American· Healthcare· Biotechnology· CUSIP 74365A309
$2.54-2.68%Price as of Aug 29, 18:33 UTC · updated once a day, after the close
Key metrics
- Market cap
- $204.65M
- P/E
- 11.5x
- Forward P/E
- 4.1x
- P/B
- 3.0x
- Dividend yield
- —
- Payout
- —
- EPS
- $0.22
- ROE
- 31.23%
- Profit margin
- 23.50%
- Revenue growth
- +27.10%
- Beta
- 0.01
- 52-week high
- $3.19
- 52-week low
- $1.52
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▲ +140.7% over 5Y.
today you would have $2,045.11▲ +104.5%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 17 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $1.80 | $1.88 | $1.78 | $1.37 | $0.83 | $3.63 | $3.28 | $3.10 | $6.60 | $4.50 | $10.20 | $18.40 | $38.90 | $51.90 | $49.30 | $99.80 | $66.20 | |
Fair price, seven ways
Seven formulas applied to what the company reported. None of them predicts a price — each answers what the stock would be worth if its assumption held. The assumption is printed next to every number, because it is the assumption that produces the result.
Earnings
$2.03
Square root of 22.5 × earnings × book value — the two ceilings Graham proposed. Blind to intangibles, so it undervalues software and brands.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
$4.93
Median P/E of 22.4 among peers in the sector.
Earnings
$3.95
Median P/E of 18.0 across the years on record for this company itself. Answers whether it is cheap against its own past, which a whole sector trading low cannot flatter.
Cash flow
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Operating
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| PEPGPepGen Inc. | $2.98 | — | 1.7x | — | -75.45% | $206.12M |
| CUECue Biopharma, Inc. | $27.88 | — | 63.1x | — | -1603.48% | $202.53M |
| RXSTRxSight, Inc. | $4.85 | — | 0.8x | — | -17.34% | $201.73M |
| ORMPOramed Pharmaceuticals Inc | $5.03 |
About the company
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
- 226
- Hackensack, United States
Company description provided by Yahoo Finance.